Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab first-line monotherapy in cisplatin-ineligible advanced or metastatic urothelial cancer
NL-OMON46877Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in transitional cell carcinoma (TCC) and bladder cancer, sponsored by Merck & Co. Primary endpoint: Objective response rate. Started Feb 2016; status: active, not recruiting.
02
Drugs
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON46877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46877.